Oral Mucositis Market

Oral Mucositis Market Analysis

The Oral Mucositis Market size is estimated at USD 1.03 billion in 2025, and is expected to reach USD 1.44 billion by 2030, at a CAGR of 7.03% during the forecast period (2025-2030).

The increasing prevalence of cancer, autoimmune diseases, and infections, along with improvements in treatment options and heightened awareness and diagnosis, are anticipated to drive the growth of the oral mucositis market during the forecast period.

Increasing cancer cases and the rising use of chemotherapy and radiotherapy are primary drivers fueling the demand in the oral mucositis market. For instance, according to the October 2023 report of Macmillan Cancer Support, the incidence of cancer in the United Kingdom is increasing rapidly. About 3.5 million people in the United Kingdom are expected to suffer from cancer in 2025, and this number is projected to reach 4 million by 2030. The high number of cancer cases may lead to higher use of cancer treatments like chemotherapy and radiation, which are common causes of oral mucositis. This increases the demand for effective mucositis management solutions, thus bolstering the market growth.

Similarly, as per an article published in Cancer Research and Treatment, in March 2024, about 34,404 new lung cancer cases are expected to be diagnosed in South Korea in 2024, compared to 32,606 lung cancer cases diagnosed in the previous year. Lung cancer patients often undergo chemotherapy and radiation therapy, which can lead to oral mucositis. The increased use of these treatments due to rising lung cancer cases may drive the demand for products that manage and alleviate mucositis symptoms.

Furthermore, the advancements in treatment options for oral mucositis among patients receiving hematopoietic stem cell transplants are further anticipated to boost the market's growth over the forecast period. For instance, according to an article published in Support Care Cancer in August 2023, it was observed that oral cryotherapy is an effective method to prevent oral mucositis (OM) induced by chemotherapeutic agents, such as melphalan (Mel) as well as in allogeneic hematopoietic stem cell transplantation recipients in the cases without methotrexate (MTX) for graft-versus-host disease (GVHD) prophylaxis. Oral cryotherapy is a valuable treatment option for oral mucositis, and its efficacy in providing symptomatic relief may increase its demand in the market, propelling the market growth.

Therefore, owing to the rising burden of cancer, advancements in treatment options for oral mucositis, and new product launches, the market studied is expected to grow over the forecast period. However, due to the high cost of treatment, limited awareness and diagnosis of oral mucositis, side effects, and limited efficacy of existing treatments, the market is likely to impede over the forecast period.

Oral Mucositis Market Trends

The Chemotherapy-induced Segment is Expected to Witness Significant Growth Over the Forecast Period

The chemotherapy-induced oral mucositis segment is expected to witness significant growth over the forecast period owing to the rising burden of cancer among the population, rising adoption of chemotherapy as the treatment choice, and growing treatment options for chemotherapy-induced oral mucositis conditions in the market.

Chemotherapy is a common treatment for various cancers and is well-known to cause oral mucositis as a side effect. The favor of chemotherapy among cancer patients directly increases the demand for products and treatments to manage their oral mucositis. For instance, according to 2024 data published by the American Cancer Society, about 35,780 new cases of multiple myeloma are expected to be diagnosed (19,520 in men and 16,260 in women) in the United States in 2024, as compared to 35,730 in 2023. Similarly, as per the National Breast Cancer Foundation, about 310,720 women are expected to be diagnosed with invasive breast cancer in 2024 in the country. These data underscore the rising number of cancer cases, driving the demand for treatments like chemotherapy. However, this also elevates the risk of developing chemotherapy-induced mucositis, fueling the segment's growth.

Furthermore, as the number of patients undergoing chemotherapy grows, the incidence of oral mucositis also rises. This creates a larger market for treatments and supportive care products designed to address mucositis. For instance, according to 2024 data published by Mesothelioma, about 25% of cancer patients receive chemo each year in the United States. Similarly, as per data published in Cancer Care in May 2023, it was observed that about 12% of females with breast cancer (stage 1 and 2) undergo treatment involving mastectomy plus chemotherapy, and 10% of the people with colon cancer undergo colectomy and chemotherapy. This data demonstrates the high adoption of chemotherapy treatment options among cancer patients, which raises their risk of developing oral mucositis, which, in turn, is anticipated to drive the growth of the oral mucositis market over the forecast period.

Various studies were conducted to assess the effectiveness of oral solutions in the management of oral mucositis among patients undergoing chemotherapy. For instance, according to a study conducted in the Babylon Oncology Center at Babylon Governorate, published in Oncology and Radiology in September 2023, it was observed that the application of a magic solution enhanced the chemotherapy-induced oral mucositis. This demonstrated that magic solution is effective for treating oral mucositis. Thus, such studies are anticipated to boost the adoption of oral solutions for the management of oral mucositis among the population, which is expected to spur market growth over the forecast period.

Therefore, owing to the rising burden of cancer cases, the adoption of chemotherapy as a treatment option, and growing research studies, the segment studied is anticipated to grow over the forecast period.

North America is Expected to Hold Significant Market Share Over the Forecast Period

North America is poised for substantial market growth during the forecast period, driven by factors such as a high cancer incidence, the adoption of advanced treatments like chemotherapy and radiation, a robust healthcare infrastructure, and significant R&D investments leading to novel treatments and product launches by key players.

North America has a pronounced prevalence of cancers, notably head and neck, hematological, and lung. The rising application of chemotherapy and radiation not only underscores the region's cancer treatment approach but also heightens the occurrence of oral mucositis, a condition anticipated to drive market expansion. For instance, according to the 2024 data published by the American Cancer Society, about 234,580 new cases of lung cancer are expected to be diagnosed in the United States in 2024. Similarly, the 2023 report from Canadian Cancer Statistics revealed a rise in cancer cases from 233,000 in 2022 to 239,000 in 2023 in Canada. This escalating cancer burden signals the growth of the oral mucositis market in the region over the forecast period.

Additionally, the increasing prevalence of type 1 diabetes among the population can manifest as oral mucositis symptoms or complications. These conditions often lead to oral cavity inflammation and ulcers, heightening the demand for specialized treatments. For instance, as per 2024 data published by the American Diabetes Association in the Statistics About Diabetes report, about 2.5 million Americans had type 1 diabetes in 2022, compared to 2 million people in 2021. Given that type 1 diabetes heightens susceptibility to oral health issues like oral mucositis due to factors like weakened immunity and reduced saliva production, the market is set for growth over the forecast period.

Furthermore, with the growing number of new product launches and approvals by regulatory bodies, the market is witnessing a surge in novel oral mucositis treatments, leading to heightened adoption and market expansion. For instance, in February 2023, Galera Therapeutics' new drug application for avasopasem manganese (GC4419), targeting radiotherapy-induced severe oral mucositis in head and neck cancer patients, received a priority review from the US Food and Drug Administration. Avasopasem acts as a selective small molecule dismutase mimetic, safeguarding normal cells from radiation damage.

Similarly, in March 2023, EpicentRx Inc. received Fast Track Designation from the US Food and Drug Administration for its RRx-001, a direct NLRP3 inhibitor and Nrf2 upregulator with anti-inflammatory and antioxidant properties, for the prevention/attenuation of severe oral mucositis in chemotherapy and radiation-treated head and neck cancer patients. Thus, the rising approvals of new drugs for treating oral mucositis are anticipated to propel their adoption, further bolstering the market growth over the forecast period.

Therefore, owing to the growing burden of cancer and the number of new product launches and approvals, the market studied is expected to grow over the forecast period.

Oral Mucositis Industry Overview

The oral mucositis market is fragmented owing to the presence of a large number of key players dominating the market. These players are adopting strategic activities such as new product launches and collaborations to retain their market share. Also, the companies are focusing on developing novel drugs for the treatment of oral mucositis. Some of the key players in the market are Innovation Pharmaceuticals Inc., Galera Therapeutics Inc., Jaguar Health Inc., Soligenix Inc., Amgen Inc., and Enzychem Lifesciences.

Oral Mucositis Market Leaders

Oral Mucositis Market News

• April 2023: Jaguar Health Inc. signed an exclusive 5-year in-license agreement with the UK-based Venture Life Group PLC. This agreement was signed for Venture Life's FDA-approved oral mucositis prescription product, Gelclair, for the US market.
• April 2024: Napo Pharmaceuticals expanded its footprint to include cancer-related supportive care and recent in-licensing of the oral mucositis product Gelclair. The company planned to commercially launch FDA-approved Gelclair prescription gel for oral mucositis in Q3 2024.